<DOC>
	<DOCNO>NCT00771147</DOCNO>
	<brief_summary>Evaluation efficacy safety Nexavar ® advance Renal Cell Carcinoma ( RCC ) calculation relate medical cost .</brief_summary>
	<brief_title>A Trial Evaluate Characteristics Patients Treated Advanced Renal Cell Carcinoma With Nexavar ®</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients diagnosis advance RCC decision take investigator prescribe Nexavar® . The patient sufficient knowledge French Dutch able participate Study Exclusion criterion must read conjunction Belgian product information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Advanced Renal Cell Carcinoma ( RCC )</keyword>
</DOC>